How Reimbursement Actually Works in Poland
This paper explains how reimbursement in Poland actually works for MedTech, IVD, digital health, and AI technologies — including the role of NFZ, DRGs (JGP), outpatient reimbursement, and AOTMiT review pathways.
How a technology actually triggers national review in Poland
In Poland, the Ministry of Health does not review technologies because a manufacturer asks.
It reviews them because containment fails. There is no application that forces attention upward. What moves a technology from local tolerance to national scrutiny is pressure that becomes politically or fiscally uncomfortable.
That pressure usually emerges in one of four ways. How reimbursement decisions are triggered in Poland (NFZ, hospitals, AOTMiT)
First, scale. When a technology spreads beyond isolated sites and its cumulative cost begins to threaten hospital balance sheets, the issue migrates. What was once a local absorption problem becomes a system problem — and the Ministry is forced to notice.
Second, concentration. Technologies associated with high-cost care, severe disease, or visible access inequities surface faster. Denial becomes harder to defend, particularly when clinical practice diverges between regions.
Third, classification stress. When a technology no longer fits cleanly inside existing coding or payment logic — when DRGs misclassify cases, outpatient acts become distorted, or volumes drift NFZ flags the anomaly. This is often the technical trigger for Ministry involvement.
Fourth, policy alignment. Technologies that intersect with declared national priorities — oncology, rare diseases, antimicrobial resistance, workforce pressure find traction more quickly. Not because they are better, but because they are legible within an existing policy narrative.
Manufacturers who succeed in Poland do not lobby for review directly. They engineer inevitability: multi-site adoption, consistent use, credible evidence of budget distortion, and visible inequity if funding remains unresolved.
At that point, the Ministry does not ask whether to review the technology.
It asks how to contain it.
How do I get reimbursed?
In Poland, that question is already misaligned.
The system does not begin by deciding whether a technology is worthy of payment. It begins by deciding who carries financial risk when that technology is introduced and how visible that risk becomes.
Reimbursement, when it happens at all, is not a starting point. It is a late-stage response to pressure.
Who Pays and Who Does Not
Poland’s healthcare system is dominated by a single public payer, the Narodowy Fundusz Zdrowia (NFZ) (National Health Fund). Formally, the NFZ finances healthcare. In practice, it fixes its exposure in advance.
The NFZ does not buy technologies.
It buys activities through fixed contracts, capped volumes, and predetermined tariffs.
Once those contracts are signed, the NFZ’s financial risk is closed. Any cost growth beyond them is not a payer problem. It is a provider problem.
This single design choice explains almost everything that follows.
In Poland, the language of reimbursement often obscures a simpler truth: the system does not pay for technologies, it pays for containment. Operationally, ICD-10 remains the binding standard for pathology reporting and for assigning hospital cases to payment categories, while ICD-11 functions largely as a strategic horizon — shaping system architecture, interoperability ambitions, and future policy design, but not yet the mechanics of payment. That distinction matters, because reimbursement in Poland is governed not by classification elegance, but by fiscal discipline enforced through rigid payment envelopes.
Hospital care is financed through Diagnosis-Related Groups, known locally as Jednorodne Grupy Pacjentów (JGP). A patient is admitted, coded using ICD-10 diagnoses and national procedure codes, and assigned to a JGP with a fixed tariff. The hospital is paid that amount no more, no less regardless of what the case actually costs. The payer, the Narodowy Fundusz Zdrowia, contracts hospitals annually with capped volumes, fixed prices, and minimal flexibility. JGPs are not prices to be negotiated; they are ceilings not to be crossed. They do not itemise diagnostics, they do not recognise devices, and they do not automatically adjust when care improves. Everything — staff, consumables, IT systems, diagnostics, devices — must fit inside the tariff. Any innovation that raises costs without changing the group is, by definition, absorbed by the hospital.
Outpatient care follows a different administrative route but the same economic logic. Specialist outpatient services (Ambulatoryjna Opieka Specjalistyczna, AOS) are reimbursed per defined medical act, each with a fixed price, strict eligibility criteria, capped volumes, and heavy audit. Diagnostics are typically bundled into visits or reimbursed only if explicitly listed; new tests or digital tools have no automatic pathway to payment and must be absorbed locally. Primary care (Podstawowa Opieka Zdrowotna, POZ) is funded almost entirely through capitation — a fixed payment per registered patient — with recent reforms introducing limited diagnostic budgets and coordinated care pilots. These reforms create permission, not funding: budgets remain capped, uptake uneven, and scrutiny intense. Separate diagnostic funding exists, but only in narrow, politically mediated programmes designed to contain exceptions rather than enable scale.
Across inpatient and outpatient care, the pattern is consistent. The NFZ fixes its exposure. Providers manage within closed envelopes. Technologies are expected to adapt to budgets, not the other way around. This is why ICD-10 continues to dominate reimbursement logic even as ICD-11 reshapes system design; why cost-saving arguments so often fail unless they release cash locally and immediately; and why innovation tends to stall not at the regulator, but at the hospital finance desk. In Poland, reimbursement is not a reward for value. It is the system’s last line of defence against uncertainty.
Why Technologies Enter as Costs, Not Revenue
In Poland, reimbursement follows activities, not innovation.
Hospitals are paid for episodes of care, primary care for populations, and outpatient clinics for defined acts. Devices, diagnostics, and digital tools sit outside that logic. They do not trigger payment; they draw on it.
A new technology therefore arrives not as a revenue line, but as a claim on an already-fixed budget. Financially, it is not recognised as progress. It is recognised as pressure.
This is why adoption fractures so predictably. Clinicians see improvement. Finance teams see dilution. The care pathway gets better, but the payment envelope does not move.
Unless a technology can displace an existing reimbursed activity, compress cost within a tariff, or release cash in the same ledger that pays for it, it remains an unfunded enhancement.
In Poland, value is not ignored.
It is simply not paid for unless it changes the arithmetic.
Why “Cost-Saving” Arguments Rarely Land
Manufacturers often argue that a technology reduces complications, shortens stays, or avoids procedures. The logic is reasonable. The impact is limited.
Hospitals respond only to savings that release cash savings that are immediate, local, and visible in the same budget that bears the cost. Savings that appear later, occur elsewhere, or benefit the system rather than the provider are treated as hypothetical. The price of the technology, by contrast, is immediate and real.
From the hospital’s perspective, adopting such a technology is not an efficiency gain. It is a transfer of financial risk.
This is why cash-release models matter and why most fail.
A credible cash-release model does not start with total system savings. It starts with the hospital ledger. It shows, explicitly:
- Which cost line is reduced (staff hours, bed-days, theatre time, consumables),
- Whether that cost is variable or fixed in the short term,
- How quickly the reduction materialises within the contract year,
- Who captures the released cash, and in which department.
Models that rely on average cost reductions, long-term projections, or downstream payer benefits rarely persuade. Models that demonstrate fewer loss-making cases, reduced length-of-stay dispersion, or avoided high-cost outliers are more legible — because they stabilise delivery within existing tariffs.
In Poland, the most persuasive economic argument is not that a technology saves money in theory.
It is that it makes the hospital financially safer to run.
Value that does not free cash does not travel.
DRGs: The Boundary You Must Design Around
Diagnosis-Related Groups in Poland Jednorodne Grupy Pacjentów (JGP) are not prices. They are ceilings.
A DRG does not describe what care costs. It describes what the payer is prepared to tolerate. Hospitals treat it as a hard boundary.
When a technology is proposed, the internal question is simple:
If we add this, where does the money come from?
If the answer is unclear, the technology is not rejected. It is contained — used selectively, justified case by case, or quietly sidelined.
Hospitals survive by managing variability inside DRGs. Technologies that reduce catastrophic outliers, stabilise length of stay, or make costs more predictable tend to fare better than those that merely improve averages.
This is why a technology can be cost-effective and still financially toxic.
Absorption Is the Default
The unavoidable conclusion is this:
Most technologies in Poland are expected to be absorbed.
Absorption means use without dedicated funding, tolerated as long as budgets hold. Over time, use often plateaus or recedes, not because the technology failed, but because it never found a budgetary home.
Manufacturers often misinterpret this as an evidence problem. More often, it is a cash-flow problem.
When Reimbursement Becomes Visible and Why It’s Rare
Visible reimbursement in Poland occurs only when absorption fails.
This happens when:
- cumulative costs can no longer be contained locally,
- access disparities become politically uncomfortable,
- or a technology aligns with a national priority.
Only then do formal mechanisms activate HTA via the Agencja Oceny Technologii Medycznych i Taryfikacji (AOTMiT), special programmes, or tariff discussions.
These mechanisms exist to contain risk, not to reward innovation. They are narrow, slow, and tightly controlled. A positive assessment changes the conversation, not the arithmetic.
Tariff change is the slowest lever of all. It is an outcome, not a strategy.
So How Do You Actually Get Reimbursed in Poland?
Reimbursement does not follow proof of benefit. It follows proof of financial tolerability. Technologies are not funded because they improve care; they are funded, eventually, because the system learns it can live with them.
In practice, technologies that survive in Poland tend to do one or more of four things:
They substitute for an already reimbursed activity, rather than adding a new one.
They compress cost within existing DRGs, by shortening episodes or stabilising resource use.
They reduce loss-making outliers, protecting hospitals from cases that break tariff logic.
They release cash locally and visibly, where decisions are actually made.
Technologies that improve outcomes without altering cash flow rarely scale. Not because their benefits are disputed, but because they do not change who carries financial risk.
In Poland, reimbursement is not granted for what is best.
It accrues slowly, which proves it does not destabilise the system.
Poland’s system is internally consistent:
The Narodowy Fundusz Zdrowia (NFZ) fixes its financial exposure through capped contracts and fixed tariffs. Hospitals manage delivery risk within those constraints, absorbing cost variability inside DRGs and outpatient budgets. Formal health technology assessment, via AOTMiT, is triggered primarily when local containment fails and costs become nationally visible.
Reimbursement, in this context, is not an access mechanism but a control instrument. It stabilises expenditure rather than rewards innovation.
For manufacturers, this has practical consequences. Technologies succeed not by demonstrating abstract cost-effectiveness, but by showing financial compatibility at the point of use: immediate cash release, reduced variance within payment envelopes, or substitution of already reimbursed activities. Evidence that speaks to hospital risk — length-of-stay dispersion, avoidance of loss-making outliers, predictable resource use — travels further than long-term system savings.
Poland is therefore not inaccessible, but conditional. Market entry requires pricing and evidence strategies designed for absorption, not entitlement. Technologies that wait for formal reimbursement before adoption rarely scale; those that first prove they do not destabilise provider finances are the ones the system eventually learns to tolerate — and, in rare cases, to formalise.
Outpatient
In Polish outpatient care, reimbursement follows acts, not tools. Tests and procedures are paid only when they are formally recognised as billable activities. Everything else is expected to disappear into someone else’s budget.
The entire outpatient system is purchased by a single payer, the Narodowy Fundusz Zdrowia (NFZ). Unlike systems that negotiate prices service by service, the NFZ contracts providers within closed financial envelopes. Once those envelopes are fixed, clinical usefulness becomes secondary to financial permission.
Most outpatient diagnostics and procedures sit inside Ambulatoryjna Opieka Specjalistyczna (AOS). Under AOS, providers are reimbursed only for services that appear on a national list, each defined by a code, a fixed price, strict eligibility criteria, and capped volumes. If a diagnostic appears on that list, it can be billed. If it does not, it cannot — regardless of how much it improves decision-making.
This is where many MedTech and IVD products stall. A new test does not become reimbursable because it adds information. Unless it replaces an existing listed service or is formally added as a new act, its cost is absorbed by the provider. The expense is immediate and local; the reimbursement is theoretical.
Primary care follows a different route, but not a freer one. Podstawowa Opieka Zdrowotna (POZ) is funded largely through capitation: providers are paid per registered patient, not per test. Recent reforms have introduced limited diagnostic budgets and coordinated care programmes, but these create permission rather than security. Budgets remain capped, uptake varies regionally, and every additional test is scrutinised. Most new diagnostics are tolerated temporarily, not funded sustainably.
There are rare exceptions. Certain tests may receive separate funding through national programmes or disease-specific pathways, usually when political pressure or access inequities force the system’s hand. These routes are slow, tightly controlled, and difficult to scale. They exist to contain risk, not to encourage innovation.
Across outpatient care, the rule is consistent:
if a test does not trigger a recognised billable act, it is not reimbursed.
Clinicians may use it. Hospitals may tolerate it. But financially, it must live inside an existing payment.
This is why outpatient reimbursement in Poland feels paradoxical. The system is not hostile to diagnostics. It is indifferent to them unless they change billing logic.
In Poland, outpatient reimbursement is not about proving value.
It is about earning a place on the list — or learning how to survive without one.
References
Narodowy Fundusz Zdrowia (2024)
Rules for reimbursement and payment of healthcare services. Warsaw: NFZ.
https://www.nfz.gov.pl
Narodowy Fundusz Zdrowia (2023)
Hospital reimbursement tariffs: Jednorodne Grupy Pacjentów (JGP). Warsaw: NFZ.
https://www.nfz.gov.pl/finanse
Agency for Health Technology Assessment and Tariff System (2024)
Health technology assessment for reimbursement decisions. Warsaw: AOTMiT.
https://www.aotmit.gov.pl
Agency for Health Technology Assessment and Tariff System (2023)
Economic evaluation methods for reimbursement applications. Warsaw: AOTMiT.
https://www.aotmit.gov.pl/wytyczne
Ministry of Health (2023)
Outpatient specialist care reimbursement rules. Warsaw: Ministry of Health.
https://www.gov.pl/web/zdrowie
Organisation for Economic Co-operation and Development (2023)
Reimbursement and provider payment in Poland. Paris: OECD Publishing.
https://www.oecd.org/health/
Panteli, D. et al. (2016)
‘Reimbursement decision-making for health technologies in Europe’, Health Policy, 120(9).
https://doi.org/10.1016/j.healthpol.2016.07.004
Kowalska-Bobko, I. and Mokrzycka, A. (2018)
‘Healthcare financing and reimbursement reform in Poland’, Health Economics Review, 8(1).
https://doi.org/10.1186/s13561-018-0197-z
How does reimbursement in Poland actually work?
Reimbursement in Poland is activity-based and budget-capped, not product-based. The public payer, Narodowy Fundusz Zdrowia (NFZ), purchases predefined healthcare activities through annual contracts with fixed prices and volume limits.
Hospitals, outpatient clinics, and primary care providers are paid for episodes, visits, or listed acts. Devices, diagnostics, and digital tools are not reimbursed as standalone items. Unless funding rules or coding structures change, technologies must be absorbed within existing payments.
Can a MedTech or IVD company apply directly for reimbursement in Poland?
No. Poland does not operate a general application pathway for routine reimbursement of MedTech, IVD, or digital health technologies.
There is no equivalent to a “coverage request” or “technology submission” that manufacturers can initiate independently. Technologies enter the system bottom-up, through local provider adoption, not top-down approval.
Formal review occurs only when financial pressure escalates beyond local containment.
Who decides whether a technology is used in practice?
Initially, hospitals and providers decide.
Clinical leaders may assess safety, workflow impact, and clinical usefulness. But the decisive question is financial:
Can this technology be delivered within our existing NFZ contract, DRG tariffs, or outpatient budgets?
If the answer is yes, the technology may be used quietly.
If the answer is no, adoption usually stops — regardless of clinical merit.
What is the DRG system in Poland?
Poland’s hospital payment system is based on Diagnosis-Related Groups called Jednorodne Grupy Pacjentów (JGP).
Each inpatient case is assigned to a JGP using:
- ICD-10 diagnosis codes, and
- national procedure classifications (e.g. ICD-9-PL).
Each JGP has a fixed national tariff, paid per case.
Crucially, this tariff functions as a financial ceiling, not a negotiated price. Hospitals bear the full cost of any care that exceeds it.
Do DRGs reimburse diagnostics, devices, or digital tools?
No. JGPs reimburse cases, not components.
All diagnostics, devices, consumables, software, and staff time must fit inside the JGP tariff unless the technology:
- replaces an already reimbursed activity, or
- materially changes coding, case classification, or length of stay.
Innovation does not trigger automatic tariff updates.
How are outpatient tests and procedures reimbursed in Poland?
Outpatient reimbursement follows the same logic: acts, not tools.
The main mechanisms are:
- AOS (Ambulatoryjna Opieka Specjalistyczna)
Specialist outpatient care reimbursed per explicitly listed medical act, each with:- a code,
- a fixed national price,
- strict eligibility rules,
- capped annual volumes.
- POZ (Podstawowa Opieka Zdrowotna)
Primary care funded mainly through capitation, with limited, tightly controlled diagnostic budgets.
A test or procedure is reimbursed only if it appears as a recognised billable act. If it does not, the provider must absorb the cost.
What role does AOTMiT play in reimbursement decisions?
AOTMiT conducts formal health technology assessment, but only exceptionally.
HTA in Poland is typically triggered by:
- the Ministry of Health, or
- NFZ,
once a technology has become a national financial issue. AOTMiT is not a routine entry point for manufacturers and does not function as an early access gateway.
HTA is used to legitimise containment decisions, not to scout innovation.
How does a technology trigger national-level review in Poland?
National review is triggered by pressure, not applications.
Common triggers include:
- widespread local adoption creating cumulative cost exposure,
- visible access inequities between regions or hospitals,
- disruption to DRG logic or outpatient coding,
- alignment with politically prioritised areas (e.g. oncology, AMR).
Technologies become visible only when they are financially unavoidable.
Why do cost-saving arguments often fail in Poland?
Because hospitals respond to cash release, not abstract savings.
Savings matter only if they are:
- immediate,
- local,
- and visible in the same budget line that pays for the technology.
Savings that occur later, elsewhere, or “for the system” are treated as hypothetical. The technology’s cost, by contrast, is immediate and real. Adoption therefore represents a transfer of financial risk to the provider.
So how do you actually get reimbursed in Poland?
You don’t begin with reimbursement. You begin with survivability.
Technologies that succeed typically do at least one of the following:
- replace an existing reimbursed activity,
- shorten a reimbursed episode within a DRG,
- reduce catastrophic, loss-making cases,
- release cash locally and visibly.
In Poland, reimbursement follows stability, not innovation.
What is the single most important takeaway for manufacturers?
Reimbursement in Poland is not a door you open.
It is a ceiling you learn to live under until the system decides it can no longer ignore you.